Syphilis
Conditions
Interventions
Drug intake group:Take 200mg of doxycycline within 24 hours of high-risk behavior. If the cumulative dose reaches 200mg per day, the drug will not be taken on the same day. After the cumulative weekly
Control group:Have syphilis/HIV test every three months.
Sponsors
Dermatology Hospital, Chinese Academy of Medical Sciences (Institute of Dermatology, Chinese Academy of Medical Sciences)
Eligibility
Sex/Gender
Male
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 18 and 70 years. 2.Currently free from syphilis, HIV, or genital Chlamydia trachomatis infection. 3.Individuals assigned male at birth (AMAB) with a history of male-to-male sexual behavior (MSM), who have engaged in one or more of the following high-risk sexual practices within the past 6 months: (1)Engaged in unprotected anal intercourse (2)Had >=2 male sexual partners (3)Self-reported history of sexually transmitted infections (STIs) other than HIV (e.g., syphilis, genital herpes, gonorrhea, chlamydial infection, chancroid, or lymphogranuloma venereum) with documented treatment completion (4)Previous or current use of HIV pre-exposure prophylaxis (PrEP) or post-exposure prophylaxis (PEP), or ongoing participation in HIV prevention trials 4.No history of tetracycline antibiotic use within the preceding 3 months. 5.Absence of severe hepatic or renal dysfunction based on medical history, with no evidence of active hepatitis B or C virus infections. 6.Demonstrated understanding of study objectives, protocol design, and potential outcomes, with voluntary consent to participate through written informed consent.
Exclusion criteria
Exclusion criteria: 1.Severe allergies or allergies to tetracycline components. 2.Patients with severe chronic diseases, metabolic diseases (such as diabetes, etc.), neuropsychiatric disorders. 3.Sick or poor compliance.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Syphilis incidence;Chlamydia trachomatis infection incidence;Incidence of adverse events in the medication group;Loses visit rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| HIV incidence;Detection rate of gonococcal drug resistance;Detection rate of chlamydia resistance; | — |
Countries
China
Contacts
Public ContactQianqiu Wang
Dermatology Hospital, Chinese Academy of Medical Sciences (Institute of Dermatology, Chinese Academy of Medical Sciences)
Outcome results
None listed